Innovation Layout
Biostar-Pharma (HKEX:2563) Focused on developing novel anticancer drugs with independent intellectual property rights A biopharmaceutical company backed by a synthetic biology R&D platform, dedicated to developing novel anti-cancer drugs with independent intellectual property rights. Its product pipeline comprises one commercialized product, Utidelone Injection, and 19 research projects under development.
CANbridge Pharmaceuticals Inc. (HKEX:1228) is a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies for rare disease. Its product layout includes biologics, small molecules and gene therapy solutions with effective action mechanisms.
JiKun Medicine is an innovation-powered drug discover and development company, focusing on developing new drugs and therapeutic approaches against organ fibrosis. JiKun has the most mature innovative anti-fibrotic drug screening and evaluation platform in China and has established a complete research and development system spanning from target discovery to clinical development, with multiple self-innovated anti-fibrotic drugs entering the clinical stage.
Focused on the R&D of ASO drugs SicaGene is a pioneering pharmaceutical company dedicated to the research and development of next-generation antisense oligonucleotide (ASO) therapeutics. Leveraging a state-of-the-art ASO drug innovation and research platform, the company enables precise regulation of target proteins, facilitates efficient ASO drug target screening, and streamlines the ASO drug development process by reducing both complexity and cost. Currently, SicaGene’s product SG12 injection has entered Phase 1 clinical trial. It also has multiple compounds have entered the clinical research stage. As a result, this company has been honored as a "National High-Tech Enterprise" and "Specialized and Sophisticated SMEs”.
